Biocon inks patent litigation settlement pact with Celgene over bone marrow cancer medicine

The company along with its subsidiaries has entered into a confidential settlement agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb.
Biocon MD Kiran Mazumdar-Shaw ( File Photo | EPS)
Biocon MD Kiran Mazumdar-Shaw ( File Photo | EPS)

NEW DELHI: Biotechnology major Biocon on Wednesday said it has entered into a settlement with Celgene Corporation regarding patents for Revlimid, a medication used to treat bone marrow cancer.

The company along with its subsidiaries has entered into a confidential settlement agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide), the Bengaluru-based company said in a regulatory filing.

It did not share details of the agreement. Celgene had filed a complaint in the US, against Biocon for potential patent infringement. Biocon shares were trading 0.45 per cent up at Rs 358.30 apiece on BSE.

Related Stories

No stories found.
The New Indian Express
www.newindianexpress.com